601607 上海医药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)6.0766.4945.5589.65010.755
总资产报酬率 ROA (%)1.9422.1021.8383.1073.259
投入资产回报率 ROIC (%)3.2643.5483.1465.5105.870

边际利润分析
销售毛利率 (%)10.54611.12912.03613.14213.225
营业利润率 (%)4.8262.9582.9463.8863.802
息税前利润/营业总收入 (%)5.3473.4523.2814.3634.350
净利润/营业总收入 (%)3.5282.1331.9853.0142.907

收益指标分析
经营活动净收益/利润总额(%)58.36494.447103.28880.31175.920
价值变动净收益/利润总额(%)48.8667.2854.7728.53619.713
营业外收支净额/利润总额(%)-0.188-1.505-8.689-2.342-0.757

偿债能力分析
流动比率 (X)1.3161.3631.3271.3511.269
速动比率 (X)1.0241.0541.0281.0390.973
资产负债率 (%)62.67562.14362.10560.63263.860
带息债务/全部投入资本 (%)43.61243.46742.10339.01138.299
股东权益/带息债务 (%)122.171124.672130.853149.257145.253
股东权益/负债合计 (%)50.32952.14052.05255.82447.293
利息保障倍数 (X)10.0976.4165.7487.7087.539

营运能力分析
应收账款周转天数 (天)105.20199.44196.60196.88892.453
存货周转天数 (天)56.73355.60555.88254.99749.202